| Dr Dona Chimene Dahl, MD | |
|
1611 Zimmerman Trl, Billings, MT 59102-7652 | |
| (406) 248-3607 | |
| (406) 248-8919 |
| Full Name | Dr Dona Chimene Dahl |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 29 Years |
| Location | 1611 Zimmerman Trl, Billings, Montana |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649205451 | NPI | - | NPPES |
| 118440700 | Medicaid | WY | |
| P00022241 | Other | MT | RR MEDICARE |
| 000083274 | Other | MT | MEDICARE |
| 0061676 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | 8220 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Vincent Healthcare | Billings, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Ob-gyn Associates, P.c. | 6608889753 | 12 |
News Archive
New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.
A clinical trial treating the papillomaviruses responsible for genital warts was on target at the halfway mark, according to Australian of the Year 2006 Professor Ian Frazer and trial manager, sexual health specialist Dr David Jardine
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment).
› Verified 4 days ago
| Entity Name | Billings Ob-gyn Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497785588 PECOS PAC ID: 6608889753 Enrollment ID: O20060713000306 |
News Archive
New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.
A clinical trial treating the papillomaviruses responsible for genital warts was on target at the halfway mark, according to Australian of the Year 2006 Professor Ian Frazer and trial manager, sexual health specialist Dr David Jardine
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dona Chimene Dahl, MD 1611 Zimmerman Trl, Billings, MT 59102-7652 Ph: (406) 248-3607 | Dr Dona Chimene Dahl, MD 1611 Zimmerman Trl, Billings, MT 59102-7652 Ph: (406) 248-3607 |
News Archive
New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.
A clinical trial treating the papillomaviruses responsible for genital warts was on target at the halfway mark, according to Australian of the Year 2006 Professor Ian Frazer and trial manager, sexual health specialist Dr David Jardine
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment).
› Verified 4 days ago
Elizabeth V Connor, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-5000 | |
Daniel M Molloy, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2900 12th Ave N, Ste 245w, Billings, MT 59101 Phone: 406-238-6010 Fax: 406-238-6022 | |
James F Metherell, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dana P. Damron, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Dana C. Edwards, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Alexis N Hokenstad, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Christa Lynn Boggis-delacruz, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1045 N 30th St, Billings, MT 59101 Phone: 406-238-2500 |